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ATPase activityNucleotide binding domains (NBDs) of the multidrug transporter of Candida albicans, CaCdr1p, possess
unique divergent amino acids in their conserved motifs. For example, NBD1 (N-terminal-NBD) possesses
conserved signature motifs, while the same motif is divergent in NBD2 (C-terminal-NBD). In this study, we
have evaluated the contribution of these conserved and divergent signature motifs of CaCdr1p in ATP
catalysis and drug transport. By employing site-directed mutagenesis, we made three categories of mutant
variants. These included mutants where all the signature motif residues were replaced with either alanines
or mutants with exchanged equipositional residues to mimic the conservancy and degeneracy in opposite
domain. In addition, a set of mutants where signature motifs were swapped to have variants with either both
the conserved or degenerated entire signature motif. We observed that conserved and equipositional
residues of NBD1 and NBD2 and swapped signature motif mutants showed high susceptibility to all the
tested drugs with simultaneous abrogation in ATPase and R6G efﬂux activities. However, some of the
mutants displayed a selective increase in susceptibility to the drugs. Notably, none of the mutant variants
and WT-CaCdr1p showed any difference in drug and nucleotide binding. Our mutational analyses show not
only that certain conserved residues of NBD1 signature sequence (S304, G306, and E307) are important in
ATP hydrolysis and R6G efﬂux but also that a few divergent residues (N1002 and E1004) of NBD2 signature
motif have evolved to be functionally relevant and are not interchangeable. Taken together, our data suggest
that the signature motifs of CaCdr1p, whether it is divergent or conserved, are nonexchangeable and are
functionally critical for ATP hydrolysis.iotropic drug resistance; NBD,
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It iswell established that anoverexpressionofmultidrug transporter
protein CaCdr1p, belonging to the ABC superfamily, represents one of
the predominant attributes of multidrug resistance (MDR) in clinical
isolates of Candida albicans [1–9]. The protein CaCdr1p is expressed as a
single polypeptide of 1501 amino acids which is comprised of two
nucleotide binding domains (NBDs) and two transmembrane domains
(TMDs) [10]. Each TMD is made up of six transmembrane segments
(TMS) that are involved in the formation of overlapping multiplesubstrates binding sites [11]. The substrates of CaCdr1p vary enormous-
ly and include structurally unrelated compounds such as azoles, lipids,
and steroids [4,12]. Several lines of evidence from mammalian ABC
proteins suggest that transport of substrates leads to conformation
changes in the TMDs region of the protein that converts to a high-
afﬁnity substrate binding site (inward facing) to low-afﬁnity binding
site (outward facing) [13]. These conformation changes in the TMDs are
triggered by the ATP binding and hydrolysis to the NBDs [14,15]. The
NBDs are characterized primarily by the presence of several highly
conservedmotifs such asWalker A (GxxGxGKS/T, where “x” represents
any amino acid), Walker B (hhhhD; where “h” represents any aliphatic
residue), and signature C (LSGGQQ/R/KQR) motif which couples the
ATP hydrolysis to power drug extrusion [16].
We have shown that unlike other transporters of higher eukaryotes,
CaCdr1p of C. albicans does not share all the consensus conservedmotifs
of the ABC transporters. Remarkably, in contrast to the Walker A
(GRPGAGCS) and B (IQCWD) motifs of the NBD1 of CaCdr1p, which
have substitution of typical critical residues that are unique to the fungal
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the other hand, the Walker A (GASGAGKS) and B (LLFLD) motifs of the
NBD2 are well conserved [10,17,18]; however, its signature motif
(LNVEQRKRLTIGV) is degenerated (Fig. 1). The complexity and diversity
of the fungal transporters have been analyzed and reveal that the
evolutionary uniqueness present in the PDR family is highly conserved
in fungal ABC transporters [19,20]). Our group has extensively
examined the functional signiﬁcance of these unique substitutions
present in the NBD domains of CaCdr1p. We have established that the
substitution of a typical cysteine with lysine (C193K), present in
equivalent position in other ABC transporters, lead to severe abrogation
of ATP hydrolysis [21] with no effect on its binding. However, exchange
of the unique tryptophan of Walker B region of NBD1 with alanine
(W326A) resulted in reducedATPbindingwithno effect on its hydrolysis
[18]. We also showed that substitution of well-conserved aspartate with
asparagine (D327N) strongly impaired the ATPase activity without
affecting the ATP binding. Unlike the other nonfungal ABC transporters,
aspartate (D327) in the Walker B motif of NBD1 of CaCdr1p is not
involved in Mg2+ coordination and has a role in ATP catalytic cycle [22].
Thus, the unique evolutionary replacements in CaCdr1p and other yeast
ABC transporters are functionally indispensable [21–23].
Similar to the ABC transporters associated with antigen processing
(TAP) [24,25], cystic ﬁbrosis transmembrane conductance regulator
(CFTR) [26], andmultidrug resistance protein 1 (MRP1) of humans [27],
CaCdr1p presumably also forms two distinct cytosolic ATPase sites [22].
One noncanonical ATPase site is composed of three unique motifs viz
degenerated Walker A and B of NBD1 and degenerated signature motif
of the NBD2, and another canonical site is formed by the conserved
Walker A and B of NBD2 and conserved signature motif of NBD1. The
biochemical studies of TAP revealed that the mutant with two de-
generated ATPase sites show drastically reduced transport activity and
suggested that the canonical ATP binding site is critical for its functionFig. 1. Topology of CaCdr1p and sequence alignment of signature motifs from various ABC tra
other nucleotide binding domains of some known ABC transporters is shown. Signature
underlined.[24]. Several structural and biochemical studies have shown that the
signature motifs are involved in the head to tail ATPase site formation
with the Walker A and Walker B motifs of the opposite NBDs,
sandwiched with two ATP molecules [26,28–30]. The signature motif
physically contributes to the dimerization of NBDs forming two hetero-
logous nucleotide binding pockets, interacting via hydrogen bondswith
ribose and the γ-phosphate moiety of ATP [29]. A similar structure of
NBDs was also deduced for a DNA repair ABC protein Rad50 [28].
Mutation in the signature motif affects the protein function. For
example, mutation of the second conserved glycine residue (LSGGQ)
of the signature motif abolished ATP hydrolysis in human CFTR [26].
Mutation at this position in human Pgp also leads to impaired protein
function and abrogated interdomain communication [31]. The analo-
gous mutation made in the NBD1 signature motif of both the a-factor
transporter ScSte6p and the ScYdf1p transporter of Saccharomyces
cerevisiae drastically impaired the substrate transport [32,33].
Although the role of signature motifs in ATP catalysis, crosstalk
between NBD and TMD, and the ATP-mediated drug transport has been
analyzed for the mammalian ABC proteins, the role of evolutionary
divergent signature motifs of NBD of yeast ABC drug transporters
remains unexplored. This is particularly important since not only yeast
ABC drug transporters but also C family of human ABC transporters
(ABCC) possess divergent residues in their conserved motifs [1].
This study evaluates the role of signature motifs of the PDR
subfamily of the yeast ABC transporter; CaCdr1p where NBD1 has a
conserved signature motif (VSGGE) while this motif is degenerated in
NBD2 (LNVEQ). For this, we mutagenized signature motif residues
by either replacing them with alanines or replacing residues with
equiposition residues of another signature motif. We also swapped an
entire motif with either a conserved or a degenerated signature motif.
By employing drug susceptibility test, efﬂux of substrate, and ATPase
activity measurements, we show that the canonical or noncanonicalnsporters. The sequence alignment of signature motif residues in NBDs with those from
motifs of CaCdr1p are shown in bold, and the conserved and divergent residues are
1759A. Kumar et al. / Biochimica et Biophysica Acta 1798 (2010) 1757–1766signature motifs in the NBDs of CaCdr1p are functionally asymmetric
and critical.
2. Experimental procedures
2.1. Materials
Ribonucleotides (ATP), protease inhibitors (PMSF, leupeptin, pep-
statin A, aprotinin, TLCK, and TPCK), and drugs, cycloheximide (CYH),
anisomycin (ANI), Rhodamine 6G (R6G), DTT, and oligomycin, and
other molecular-grade chemicals, were obtained from Sigma Chemical
Co. (St. Louis, MO). Oligonucleotides used in this study, as listed in
Table 1 (supplementary data), were commercially procured from Sigma
Genosys, Inc. Fluconazole (FLC) was kindly provided by Ranbaxy
Laboratories (New Delhi, India). Anti-GFP monoclonal antibody and
[α-32P] 8-azido ATP (15-20 Ci/mmol) were purchased from BD
Biosciences Clontech (Palo Alto, CA) and Afﬁnity Labeling Technologies,
Inc. (Lexington, KY), respectively. The radio labeled [125I] IAAP (2300 Ci/
mmol) was procured from Perkin-Elmer Life Sciences (Boston, MA).
2.1.1. Media chemicals and strains
Plasmids were maintained in Escherichia coli, DH5α. E. coli was
cultured in Luria-Bertani medium (Difco, BD Biosciences, NJ) to which
ampicillin was added (0.1 mg/ml). The yeast strains were cultured in
YEPD broth (Bio101, Vista, CA) or SD-ura− (Bio101). Table 2 (supple-
mentary data) lists all of the strains used in this study.
2.2. Methods
2.2.1. Site-speciﬁc mutagenesis
Site directed mutagenesis was performed using the quick-change
mutagenesis system as described previously [34]. The mutations were
introduced into plasmid pPSCDR1-GFP according to the manufac-
turer's instructions, and themutated plasmid pPSCDR1-GFP linearized
with XbaI was used to transform S. cerevisiae strain, AD1-8u− cells by
the lithium acetate transformation protocol exploiting uracil proto-
trophy [34,35].
2.2.2. Immunodetection of CaCdr1p
Plasma membrane (PM) was prepared from S. cerevisiae cells
grown in YEPD to late exponential phase, as described previously [34].
The Western blot analysis was carried out using anti-GFP monoclonal
antibody (1:5000 dilution) as described previously [34].
2.2.3. ATPase activity assay
The WT-CaCdr1p associated ATPase activity of the puriﬁed PM was
measured as an oligomycin-sensitive release of inorganic phosphate as
described previously [34]. Brieﬂy, puriﬁed PM (10 μg) was incubated at
30 °C in 0.1 ml of reaction mixture containing 8 mMMgCl2 and 60 mM
Tris–HCl, pH 7.5 (ATPase reaction buffer), and 20 μMoligomycin where
indicated. To eliminate possible contributions fromnonspeciﬁc vacuolar
and mitochondrial ATPases, 50 mM KNO3 and 10 mM NaN3, respec-
tively, were included in the reaction mixture. The reaction was started
by addition of 5 mMATPandwas stoppedby the addition of 0.1 ml of 5%
SDS solution. The amount of inorganic phosphate released was
determined immediately as described previously [36].
2.2.4. Rhodamine 6G efﬂux assay
Efﬂux of Rhodamine 6G (R6G) was determined essentially using a
previously described protocol [34,37]. Brieﬂy, approximately 4×10−6
yeast cells from an overnight grown culture were transferred into
YEPD media and allowed to grow for 5 h. Cells were pelleted and
washed and then resuspended in phosphate-buffered saline (PBS) as a
2% cell suspension to which R6G was added at a ﬁnal concentration of
10 μM and incubated for 1 h at 30 °C. The cells were then washed andresuspended in PBS and reaction was initiated by the addition of 2%
glucose. Samples of 1 ml volume were withdrawn at indicated time
(30 min) and centrifuged at 9000×g for 2 min. The supernatant was
collected, and absorption was measured at 527 nm.
2.2.5. Drug susceptibility
The susceptibilities of S. cerevisiae cells to different antifungal
drugs were determined using spot assays. In this assay, 3 μl samples of
ﬁve-fold serial dilutions of each yeast culture (each with cells
suspended in normal saline to an optical density at 600 nm of 0.1)
were spotted on to YEPD plates in the absence (control) or in the
presence of the drugs [38].
2.2.6. Confocal microscopy and ﬂow cytometry
Confocal imaging and ﬂow cytometric (FACS) analysis of CaCdr1p
and itsmutant variants carrying S. cerevisiae cellswereperformedwitha
Bio-Rad confocal microscope (MRC 1024) with a 100-μl oil immersion
objective and FACS or ﬂow cytometer (Becton-Dickson Immunocyto-
metry Systems, San Jose, CA) as described previously [34].
2.2.7. Photo afﬁnity labeling with [125I] IAAP
The PM proteins (30 μg) were incubated with the indicated drug for
10 min at 37 °C in 50 mM Tris–HCl, pH 7.5, in the absence of ATP. The
samples were brought to room temperature and 7.5 nM [125I]
iodoarylazidoprazosin (IAAP) (2300 Ci/mmol) was added and incubat-
ed for an additional 5 min under subdued light. The samples were then
illuminated with a UV lamp assembly (PGC, Scientiﬁcs, Gaithersburg,
MD) ﬁtted with two black light (self ﬁltering) UV-A long wavelength
F15T8BLB tubes (365 nm) for 10 min at room temperature. Following
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) on an 8%Tris–
glycine gel at constant voltage, gels were dried and exposed to Bio-
MaxMR ﬁlm (Eastman Kodak, Rochester, NY) at−80 °C for 12 to 24 h.
The radioactivity incorporated into the WT-CaCdr1p and its mutant's
bands was quantiﬁed using a STORM 860 phosphorimager system
(Molecular Dynamics, Sunnyvale, CA) and the software Image QuaNTas
described previously [34].
2.2.8. Binding of [α-32P] 8-azido-ATP
The PM protein (30 μg) was incubated in the ATPase reaction
buffer containing 10 μM [α-32P] 8-azido-ATP (10 μCi/nmol) in the
dark at 4 °C (on ice) for 5 min in the presence or absence of 10 mM
ATP. The samples were then illuminated with a UV lamp assembly
(365-nmwavelength) for 10 min on ice (4 °C) as described previously
[39]. Following SDS–PAGE on an 8% Tris–glycine gel at constant
voltage, the gels were dried and exposed to Bio-Max MR ﬁlm at 80 °C
for 12–24 h. The radioactivity incorporated into the WT-CaCdr1p and
its mutant variants bands was quantiﬁed as described above.
3. Results
3.1. Site-directed mutagenesis of signature motif residues
Earlier structural studies have revealed that the ﬁrst ﬁve core
residues of signaturemotif (LSGGQ),which hold theATPmolecule at the
catalytic site, are critical [28,29]. Toaddress the role of signaturemotifs of
NBDs of CaCdr1p (Fig. 1), in this study, we have mutagenized the ﬁrst
ﬁve residues of both the conserved and the degenerated signaturemotifs
of NBD1 (VSGGE) and NBD2 (LNVEQ), respectively. The ﬁrst category of
mutants included variants where all the residues of both the signature
motifs were replaced with alanines such as V303A, S304A, G305A,
G306A, and E307A of NBD1 and L1001A, N1002A, V1003A, E1004A, and
Q1005A of NBD2. In the second category of mutant variants, we
substituted the position of an individual residue of a signaturemotif into
its equipositional residuepresent in another domain. For example, valine
(V303)present in theNBD1was replacedwith leucinewhich is present at
the equivalent position in NBD2. Thus, we constructed V303L, S304N,
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E1004G and Q1005E of NBD2. Finally, to further evaluate the functional
contribution of each signature motif, we swapped the entire signature
motif by introducing mutations in a way to produce two consensuses
(signature 1-1), two degenerated (signature 2-2) and swapped (signa-
ture 2-1) motifs variants which were placed in the third category.
All the mutations were introduced into the C-terminal GFP-tagged
CaCdr1p that was stably overexpressed at the PDR5 locus in a
heterologous host S. cerevisiae mutant strain, AD1-8u− and expressed
asGFP fusedCaCdr1p (WT-CaCdr1p) localized in PM[34]. The hostAD1-
8u− is deleted in seven PM-encoded major ABC transporters and is
derived froma pdr1–3mutant strainwitha gain-of-functionmutation in
the transcription factor Pdr1p, resulting in a constitutive hyperinduction
of the PDR5 promoter [34]. A single integration copy of CDR1 ORF at the
PDR5 locus in the host genome of each mutant was conﬁrmed by
Southern hybridization (data not shown).Fig. 2. Alanine scanning of the signature motifs of CaCdr1p. (A) Fluorescence imaging (upper
mutant variant protein expressing cells. Flow cytometry (lower panel) of S. cerevisiae cells ex
program depicts ﬂuorescence intensities for AD1-8u− (control) (purple ﬁlled area) and WT
the respective CaCdr1p mutant variant-expressing cells. (B) Drug resistance proﬁle of WT-Ca
as per protocol described earlier [34]. In the spot assays, 5 μl of ﬁve-fold serial dilutions of ea
spotted on YEPD plates in the absence (control) and the presence of the following drugs: FL
axis) indicated by blue diamond (♦) and oligomycin-sensitive ATPase activity (right Y-axis3.2. Substitution of signature motifs residues with alanines abrogates
function
Similar to theWT-CaCdr1p, all thealanine scanningmutantvariantsof
signature motif were equally expressed as revealed by Western blot
analysis of PM fraction of the cell (Fig. S1, supplementary data) andwere
properly surface localized as conﬁrmed by confocalmicroscopy and FACS
analysis (Fig. 2A). However, these mutant variants displayed variable
drug susceptibilities. For example, cells expressing G306A and E307A of
NBD1 and N1002A of NBD2 were hypersensitive to all the tested drugs
(Fig. 2B). The enhanced drug sensitivity was corroborated by observed
abrogated efﬂux of a ﬂuorescent substrate R6G [34]. We used intact cells
expressing different mutant variants and de-energized them and
monitored energy dependent extrusion of R6G, which was initiated by
the addition of glucose [37]. As compared to host strain AD1-8u−, cells
expressing theWT-CaCdr1pwere able to extrude higher R6G,whichwaspanel) by confocal microscope showing membrane localization of WT-CaCdr1p and its
pressingWT-CaCdr1p and its mutant variants. The histogram derived from the cell quest
-CaCdr1p (solid orange line) for each panel, and the other extra line represents that for
Cdr1p and its signature motifs mutant variants is determined by spot assay. It was done
ch yeast culture (each with cells suspended in normal saline to an OD of 0.1 (A600)) was
C, 5 μg/mL; CYH, 0.15 μg/mL; ANI, 1.0 μg/mL; and R6G 5 μg/mL. (C) R6G efﬂux (left Y-
) of WT-CaCdr1p with its mutant variants indicated by green square (■) [34,37].
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0.5 nmol R6G/ml/30 min). However, drug-hypersensitive mutant var-
iants,G306AandE307AofNBD1andN1002AofNBD2,displayedseverely
impaired R6G efﬂux and behaved like the host strain AD1-8u− (Fig. 2C).
The loss of R6G efﬂux activity in these mutants was associated with a
simultaneous impaired ATPase activity (Fig. 2C). Notably, we had earlier
observed that unlike mammalian ABC proteins, WT-CaCdr1p does not
show dramatic drug stimulated ATPase activity [40]. For this reason, we
routinelymeasure basal (unstimulated) ATPase activity. Mutants such as
S304A, L1001A, and E1004A displayed increased sensitivity to only
selected drugs. For example, the conserved serine residue of signature
motif of NBD1, when replaced with alanine (S304A), was only partially
sensitive to cycloheximide (CYH) and R6Gwhile similar toWT-CaCdr1p,
remained resistant to other drugs. In contrast, L1001A of NBD2 displayed
sensitivity toCYHwhile itwasonlypartially sensitive toﬂuconazole (FLC)
and anisomycin (ANI). All these mutant variants, which showed partial
abrogation in resistance towards selected drugs, did not show any
signiﬁcant difference in their ability to efﬂux R6G (Fig. 2C). The basal
ATPase activity, which drives active extrusion of R6G, was also com-Fig. 3. Equipositional replacements of the signature sequences of CaCdr1p. (A) Fluorescen
CaCdr1p and its mutant variant protein expressing cells. Flow cytometry (lower panel) of S.
from the cell quest program depicts ﬂuorescence intensities for AD1-8u− (control) (purple
represents the respective CaCdr1pmutant variant-expressing cells. (B) Drug resistance proﬁl
as described for Fig 2. (C) R6G efﬂux (left Y-axis) indicated by blue diamond (♦) and oligo
indicated by green square (■) [34,37].parable to the WT-CaCdr1p and was not changed. However, mutant
variant E1004A was an exception, which was sensitive to CYH and only
partly sensitive to FLC, and R6G showed only about 42% decrease in the
efﬂux of R6G (Fig. 2C). Recent studies showed that NBD residues indeed
could selectively inﬂuence susceptibility towards drugs. H1068A muta-
tion in theH-loop of Pdr5p of S. cerevisiae selectively abrogated resistance
towards tested drugs. For example, themutant variantH1068A remained
resistant to ketoconazole (KTC), FLC, and CYH, while it showed dramatic
loss of resistance to rhodamine 123 [23].
This decrease in R6G transport was coupled with a simultaneous
abrogation of ATPase activity. All the other mutant variants such as
V303A, G305A of NBD1, and V1003A and Q1005A of NBD2 had
phenotypes, similar to cells expressing WT-CaCdr1p (Fig. 2).
3.3. Restoration of conservancy in signature motifs does not support
functionality of NBDs
To further examine the functional compatibility and to underscore
signiﬁcance of the conserved and degenerated signature residues, wece imaging (upper panel) by confocal microscope showing membrane localization of
cerevisiae cells expressing WT-CaCdr1p and its mutant variants. The histogram derived
ﬁlled area) and WT-CaCdr1p (solid orange line) for each panel, and the other extra line
e ofWT-CaCdr1p and its signature motif mutant variants was determined by spot assays
mycin-sensitive ATPase activity (right Y-axis) of WT-CaCdr1p with its mutant variants
Fig. 4. Swapping of signature motifs of CaCdr1p. (A) Schematic diagrams of different CaCdr1p signature swappedmutants variants. The entire signature motif of NBD1 (white)/NBD2
(purple) was mutated to generate constructs with two conserved (signature 1-1), two degenerated (signature 2 -2) and swapped (signature 2-1) active site (upper panel).
Localization and expression proﬁle of WT-CaCdr1p and its swapped signature mutant variants (lower panel). (B) Drug resistance proﬁle of WT-CaCdr1p and its signature motifs
swapped mutants was determined by spot assays. (C) Comparison of oligomycin-sensitive ATPase activity of WT-CaCdr1p with its swapped mutant variants. ATPase activity of the
PM fraction of cells expressing the WT-CaCdr1p and its mutant variants was assayed as described earlier [34]. (D) R6G efﬂux by the WT-CaCdr1p and its mutant variant protein-
expressing cells. The R6G efﬂux was measured as described previously [37]. The values are mean SD (±error bars) for three independent experiments.
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with their equivalent positional residue of the other domain. These
substitutions did not affect surface expression and localization of WT-
CaCdr1p as determined by confocal and FACS analysis (Fig. 3A).
Replacement of conserved serine with asparagine (S304N) to mimic
degeneracy at this position and asparagine with serine (N1002S) to
mimic conservancy in NBD2 resulted in hypersensitivity to all the tested
drugswith severelydiminishedR6GefﬂuxandATPase activities (Fig. 3C).
Similar results were also observed when highly conserved glycine of
NBD1 changed into glutamate (G306E) and its equivalent residue
glutamate of NBD2 exchanged with glycine (E1004G). Both these
mutants were hypersensitive to all the drugs with abrogated R6G efﬂux
andATPase activity (Fig. 3C). The equipositionalmutant E307Qdisplayed
drug selective phenotype,whichwashypersensitive toR6Gandwas onlyFig. 5. (A). (i) Photoafﬁnity labeling ofWT-CaCdr1p and its mutant variants with [125I]-IAAP.
was incubated with 7.5 nM [125I]-IAAP (2300 Ci/mmol). The samples were UV cross linked
antibody to ensure equal loading of WT-CaCdr1p and its signature mutant variants. (iii) No
shown in percentage. (B) Photoafﬁnity labeling ofWT-CaCdr1p and its mutant variants with
mutant variants was incubated with 10 μM [α-32P] 8-azido ATP 7.5 μCi/nmol at 4 °C and com
blot analysis using anti-GFP antibody to ensure equal loading of WT-CaCdr1p and its signa
Western blot intensity. The values are shown in percentage.partially sensitive to other drugs. This mutant variant showed 52%
abrogation in R6G efﬂux with a simultaneous loss of ATPase activity. In
contrast, the replacement of equipositional residues, such as V303L,
G305VofNBD1, and L1001V, V1003G, andQ1005EofNBD2, hadnoeffect
on the drug susceptibility, R6G efﬂux, and ATPase activity (Fig. 3).
3.4. Swapping of the signature motifs results in complete loss of function
The cells expressing the signature swappedmutants, signature1-1,
signature 2-2, and signature 2-1, were hypersensitive to all the tested
drugs and displayed severely impaired R6G efﬂux and ATPase activity
and behaved more like the host strain, AD1-8u− (Fig. 4). Nonetheless,
all the signature swapped variants were properly surface localized
and equally well expressed.The PM fraction (30 μg protein) of cells expressingWT-CaCdr1p and its mutant variants
and processed as described elsewhere [34]. (ii) Western blot analysis using anti-GFP
rmalized incorporated [125I] IAAP labeling with Western blot intensity. The values are
[α-32P] 8-azido ATP. The PM fraction (30 μg) of cells expressing theWT-CaCdr1p and its
peted with 10 mM cold ATP (+ATP lane) as described in Shukla et al. [34]. (ii) Western
ture mutant variants. (iii) Normalized incorporated [α-32P] 8-azido ATP labeling with
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mutants
We have examined if the observed impairment of function, i.e., R6G
drug transport andATPhydrolysis of signaturemutantswas due to their
inability to bind to CaCdr1p.We evaluated this aspect by using the [125I]
iodoarylazidoprazosin (IAAP) and [α-32P] 8-azido ATP, which are
photoafﬁnity analogues of substrate prazosin and ATP, respectively.
We performed the binding experiments with both the signature motifs
of NBDs by selecting three signature motif (VSGGE) residues S304,
G306, and E307 of NBD1 and equivalent position residues of signature
motif (LNVEQ) of NBD2 viz. N1002, E1004, and Q1005. The selection of
these residues was based on our data (this study) and from the crystal
structure of MJ0796, an ABC protein of Methanocaldococcus jannaschii,
which showed that these residues are part of ATPase bindingpocket and
interact with the ATP moiety [29]. All the signature motif mutant
variants at a ﬁxed concentration efﬁciently cross linked to [125I] IAAP
comparable to that of WT-CaCdr1p. An equivalent amount of PM
derived from thehost cells (AD1-8u−)wasusedas a control,whereinno
binding of [125I] IAAP was observed (Fig. 5A). We have earlier shown
that [125I] IAAP efﬁciently cross linkedwithWT-CaCdr1p and its binding
can be competed out with molar excess of nystatin and the binding of
[3H] azidopine, a dihydropyridine photoafﬁnity analogue, is competed
out with miconazole [34]. In this study, the competition experiments
with drugs were not done since none of the drugs used in this study,
which showed selective susceptibilities, compete with [125I] IAAP
binding [34]. Thus, [125I] IAAP binding, which did not change in the
signaturemutant variants, provides limited information andmay not be
a true indicator of drug binding sites of WT-CaCdr1p.
In addition, all the signature mutant variants were assessed for [α-
32P] 8-azido ATP binding, which was normalized by Western blot
analysis. No cross linking was observed of this analogue with the host
cell (AD1-8u−) membrane, which served as negative control. Notably,
binding of 8-azido-[α-32P] ATP to all signature mutant variants was
similar to WT-CaCdr1p, which was competed out with a molar excess
of the cold ATP (Fig. 5B).4. Discussion
Signature motifs are the hallmark sequences of NBDs of ABC
transporters which display highly conserved sequences across the
evolutionary scale; however, there are instances of the appearance of
selective divergence within this motif. For example, human ABC
transporters such as TAP [24] and CFTR [26] have degenerated
signature motifs (Fig 1). In contrast, all the family members of ABC
transporters of fungi, particularly of PDR subfamily, display diver-
gence in their signature motifs. Thus, the signature motif of NBD1 of
CaCdr1p is well conserved but has NBD2with a degenerated signature
motif (Fig. 1). In the present study, we have explored the signiﬁcance
of degeneration in the signature sequence of NBD2 versus conserved
signature motif of NBD1 of CaCdr1p. Our analysis revealed that the
conserved and degenerated signature sequences of the CaCdr1p are
functionally indispensable and cannot be exchanged. This emphasizes
the uncompromised asymmetry that exists between the NBDs of
CaCdr1p and in other yeast ABC transporters.
We show that similar to other ABC transporters, the well-conserved
serine (S304) and glycine (G306) residues present in conserved
signature motif of NBD1 are also critical for the functioning of CaCdr1p.
For example, even the substitution at the equivalent position residues of
degenerated signature motif of NBD2with the conserved ones and vice
versa does not support the function of the transporter (Figs. 3C and D).
In the ABC protein of Pyrococcus furiosus, Rad50, replacement of this
serine (LSGGQ) to arginine prevents dimerization of NBDs [28], and in
human CFTR, polymorphism at this residue with either asparagine,
arginine, or isoleucine results in cystic ﬁbrosis [41–43]. Furthermore, ifcysteine was introduced at this position in the CFTR protein, it resulted
in total loss of channel activity [44].
The well-conserved glycine present at the fourth position of signa-
ture motif (LSGGQ) is involved in the ATP catalysis [25,26,31,32,45,46].
Biochemical analysis revealed that a small change at this position
(G→A) results in steric hindrance betweenmethyl group of alanine and
γ-phosphate of ATP. If this glycine is exchanged with bulky, charged
aspartate or glutamate, it leads to a complete loss of ATPase and protein
activity [46,47]. The critical nature of serine and glycine inWT-CaCdr1p
can also be compared with similar residue of those proteins whose
crystal structures are known. The existing structural information
suggests that the signature motifs of ABC proteins; Rad50 of P. furiosus,
MJ1096 of M. jannaschii, GlcV of Sulfolobus solfataricus, Sav1866 of
Staphylococcus aureus, mouse CFTR, HlyB, and MalK of E. coli, are
involved in the head to tail ATPase site formationwith theWalker A and
Walker B motifs of the opposite NBDs, sandwiched with ATPmolecules
wherein the signaturemotif is a “sensor” for an ATPγ -phosphate in the
opposing domain. [28,29,48–52]. Based on the conserved nature of
thesemotifs, it is reasonable to speculate that in CaCdr1p, the conserved
S304 and G306 of NBD1 probably fall within close proximity of the ATP
binding site. In addition, divergent residues present in NBD2 signature
region is also equally important and may be part of the ATPase site as
well. However, it still requires experimental validation.
We also provide evidence that in addition to highly conserved and
critical S304 and G306 residues, the equipositional residues N1002 and
E1004 of degenerated signaturemotif of NBD2ofWT-CaCdr1phave also
evolved to be functionally essential. Notably, pairs of residue like V303
and G305 of NBD1 and L1001, V1003, and Q1005 of NBD2 signature
motif, although part of otherwise conserved signature sequences, have
apparently no functional relevance. These residues, when replacedwith
either alanines or with its equipositional substitute, continued to show
phenotypes similar to cells expressing WT-CaCdr1p.
Functional nonequivalence in the NBDs of ABC proteins of yeast is
the result of variations in the conserved motifs (Walker A, Walker B,
H-loop, and signature motif). Our earlier results have shown that the
equipositional exchange mutations such as C193K and K901C of
Walker A of CaCdr1p yielded selectively impaired functional protein
[21]. However, replacement of the entire NBD of CaCdr1p to make a
chimera with two NBD1 (NBD1/NBD1) and two NBD2 (NBD2/NBD2)
yielded nonfunctional proteins and had severe cellular trafﬁcking
problem [53]. These results had established functional asymmetry
nature of NBDs in CaCdr1p. These variations in NBD1 may have
evolved in response to the degenerated signaturemotif of NBD2. Thus,
in CaCdr1p, both canonical and noncanonical ATP binding sites are
formed similar to TAP and CFTR proteins. Recently, Ernst et al. [23,54]
hypothesized that in Pdr5p of S. cerevisiae, a close homologue of
CaCdr1p, one ATP molecule catalyzed at the canonical active site may
be sufﬁcient to reset the TMDs, whereas the second noncanonical site
(regulatory site) may be engaged to serve as platform for keeping
domains in dimeric form (inward facing).
Our equipositional replacements data of signature motifs demon-
strate that the mutant variants, S304N and G306E of NBD1 and
N1002S and E1004G of NBD2, severely impaired both transport
(Fig. 3C) and ATPase activity (Fig. 3C). These results clearly show that
both the conserved site and the degenerated site are equally
important for ATP catalysis. The signature sequence swapping data
highlights the importance of the uniqueness of the signature region of
WT-CaCdr1p. Signature swapped mutants with either two conserved
(signature 1-1) or two degenerated (signature 2-2) or swapped motif
(signature 2-1) rendered nonfunctional protein (Fig. 4) although their
surface localization and expression was not affected (Fig. 4A). In this
context, it is worth mentioning that TAP protein with two degenerate
sites shows dramatically impaired activity and thus demonstrating
that consensus site is critical. In contrast, only 10% loss in activity was
seen with TAP protein having both consensus sites. In addition,
swapping between consensus and degenerative sequences retained
1765A. Kumar et al. / Biochimica et Biophysica Acta 1798 (2010) 1757–1766more than 50% of the activity. It would mean that TAP protein can
remain partly functional if at least one of the signature motifs retains
the consensus site [24]. In contrast, NBDs of Pgp are symmetric in
function and possess conserved signature motifs at both positions.
The replacement of either serine of both signature motifs (S528/
S1173) with alanine resulted in a marginal loss in ATPase activity,
whereas double mutation at these positions in the signature motif
(S528A/S1173A) alleviates strength of interaction in the transition
state, which implies that these serine residues of P-glycoprotein
cooperatively accelerate ATP hydrolysis [55]. Taken together, our data
clearly establish that the signature motifs of NBDs are functionally
nonidentical and that the evolutionary divergence of CaCdr1p and
other members of PDR subfamily is critical and noninterchangeable.
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